Level 5 Drug Therapy Requiring Intensive Monitoring for Toxicity

August 7, 2023

We get a number of questions on this topic, and for good reason: It’s complicated!

To simplify things a little, let’s start with some common examples of what does NOT qualify for intensive toxicity monitoring:

  • Drugs that have a high therapeutic index (low toxicity).
  • Short-term drug therapy (since there is no advantage to monitoring in such cases).
  • Treatment of chronic disorders (such as antihypertensive therapy), provided you can provide an adequate assessment using noninvasive methods such as blood pressure monitoring.

So, what does qualify for Level 5 toxicity monitoring? Let’s clarify.

  • Cytotoxic chemotherapy is always considered high risk when you monitor blood cell counts as a surrogate for toxicity.
  • Some drugs with a narrow therapeutic window and a low therapeutic index may qualify for intensive monitoring because they can show toxicity when concentrations are close to the upper limits of the therapeutic range. Below are some examples of such drugs (note that this is not a complete list).
Drug Category Drugs In That Category Treatment Use
Cardiac Digoxin, digitoxin, Quindine, Procainamide, Amiodarone Congestive heart failure, angina, arrhythmias
Anticoagulants Coumadin and intravenous
Heparin drip (Heparin must be provided in a hospital setting)
Prevention of thrombosis and thromboembolisms
Antiepileptic Phenobarbitol, Phenytoin, Valproic Acid, Carbamazepine, Ethosuximide, Gabapentin (sometimes), Lamotrigine (sometimes) Epilepsy, prevention of seizures, mood stabilization (sometimes)
Bronchodilators Theophylline, Caffeine Asthma, COPD (chronic obstructive pulmonary disorder), Neonatal apnea
Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, Mycophenolate, Mofetil, Azathioprine Prevent rejection of transplanted organs, autoimmune disorders
Anti-Cancer All cytotoxic agents Multiple malignancies
Psychiatric Lithium, Valproic Acid, Some antidepressants (Imipramine, Anitripyline, Nortripyline, Doxepin, Desipramine) Bipolar disorder (manic depression), depression
Protease Inhibitors Indinavir, Ritonavir, Lopinavir, Sqauinavir, Atazanavit, Nelfinavir HIV/AIDS
Antibiotics Aminoglycosides, (Gentamicin, Tobramycin, Amikacin, Vancomycin, Chloramphenicol, Cubicin, Zyvox) Infections with bacteria that are resistant to less toxic antibiotics
Insulin / Anti-diabetic Intravenous Insulin drip Hyperglycemia
Erythropoiesis-Stimulating Agents (ESAs) Procrit and Epogen (Epoetin Alfa) and Aranesp (Darbepoetin Alfa) Anemia
Biologic Agents Infliximab, Adalimumab, Ustekinumab Rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease

Next question: How do you show toxicity monitoring in the dictation?
Some examples of places where you show toxicity monitoring:

  • Baseline assessments
  • Vital signs monitoring
  • ECG electrocardiogram monitoring
  • Blood tests (which are the most commonly used place in the dictation)
  • Imaging studies
  • Adverse event reporting (e.g., patients noticing adverse symptoms or changes in their condition)
  • Specialist consultations (toxicologists, cardiologists nephrologists, and hepatologists)

Patient education and compliance should be indicated in the dictation because patients need to be informed of potential toxicities associated with their medication and because of the need to adhere to the dosages and monitoring schedule. (Symptoms of drug toxicity should be reported to the physician immediately).

Download PDF

Michelle Sergei-Casiano
Michelle Sergei-Casiano
Michelle Sergei-Casiano

Senior Manager, Regulatory and Coding Compliance

More Coffee & Coding

ICD-10 updates: What you need to know

Coming October 1: 2024 ICD-10 Diagnosis Changes September 18, 2023 This time of year can be stressful for providers and coders. It is a time when we’re on the lookout for notifications about ICD-10 code updates. Each year, the volume of these changes appears to...

How Communication Makes for Better Documentation

How Better Communication Makes for Better Documentation September 11, 2023 Artificial Intelligence (AI) is only as good as the documentation it reads. But what does that mean? In the realm of doctor pro-fee office billing, if the documentation is unclear, AI cannot...

Coding for Social Determinants of Health

Coding for Social Determinants of Health August 28, 2023 Here’s a sobering thought for healthcare professionals: According to the National Academy of Medicine, medical care accounts for only 10% to 20% of all health outcomes. Social Determinants of Health (SDOH)...

Billing for E/M Services During the Global Period

Billing for E/M Services During the Global Period August 21, 2023 We frequently receive questions about "Global Periods" for surgical procedures. People often ask, "What are the time limits for these periods?" and "To which types of procedures do these post-op periods...

Making Sense of the Three Most Confusing Complexity of Data Categories

Making Sense of the Three Most Confusing Complexity of Data Categories August 14, 2023 Based on questions from our clients and readers, there appears to be a lot of confusion about definitions and interpretations of several categories involving “Complexity of Data.”...

Telehealth Visits: Keeping Up with the Latest Changes

Telehealth Visits: Keeping Up with the Latest Changes July 31, 2023 Now that the public health emergency is officially over, some of the coding requirements regarding telehealth visits that were put in place during the COVID-19 pandemic have been revised. To receive...

Billing Wellness Visits Under Medicare, Part III

Billing Annual Wellness Visits Under Medicare, Part III July 24, 2023 Last week, we delved deeper into the second of three types of wellness visits—Annual Wellness Visits (AWVs)—covered by Medicare. Now, let's shift our focus to Subsequent Wellness Visits (along with...

Billing Wellness Visits Under Medicare, Part II

Billing Wellness Visits Under Medicare, Part II July 17, 2023 Last week, we delved deeper into the first of three types of wellness visits—IPPEs—covered by Medicare. Now, let's do the same for the second category: Annual Wellness Visits (AWVs). AWV (Annual Wellness...

Billing Wellness Visits Under Medicare, Part I

Billing Wellness Visits Under Medicare, Part I July 10, 2023 Nobody—and I mean nobody—welcomes an audit from CMS. That means taking extra care when assigning E/M codes to outpatient visits covered by Medicare. And with that in mind, the following three editions of...

Subscribe to Our Weekly Coffee & Coding Newsletter